Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1995 1
1996 1
1997 2
1998 1
1999 1
2001 1
2003 4
2005 1
2006 1
2007 2
2008 1
2009 1
2010 1
2011 1
2012 4
2013 2
2015 3
2016 1
2017 3
2018 2
2019 1
2020 3
2021 4
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.
Tbeileh N, Timmerman L, Mattis AN, Toriguchi K, Kasai Y, Corvera C, Nakakura E, Hirose K, Donner DB, Warren RS, Karelehto E. Tbeileh N, et al. PLoS One. 2023 Apr 6;18(4):e0271354. doi: 10.1371/journal.pone.0271354. eCollection 2023. PLoS One. 2023. PMID: 37022995 Free PMC article.
In line with this, variant allele frequencies (VAFs) of oncogenes and tumor suppressor genes were undetectable or low in most patient tumors, but higher in matching organoid cultures. Positive correlation was observed between VAFs and in silico tumor purity estimates. Sequ …
In line with this, variant allele frequencies (VAFs) of oncogenes and tumor suppressor genes were undetectable or low in most patient tumors …
Differential expression of mast cell granules in samples of metastatic and non-metastatic colorectal cancer in patients.
Flores de Los Rios PA, Soto Domínguez A, Arellano-Pérez Vertti RD, Castelán Maldonado EE, Velázquez Gauna SE, Morán Martínez J, Salas Treviño D, García Garza R. Flores de Los Rios PA, et al. Acta Histochem. 2020 Oct;122(7):151618. doi: 10.1016/j.acthis.2020.151618. Epub 2020 Sep 18. Acta Histochem. 2020. PMID: 33066840
Therefore, the present work aimed to compare employing histochemistry and immunohistochemistry, the number of mast cells and the content of some cytoplasmic granules in moderately differentiated non-metastatic and metastatic colorectal adenocarcinoma, analyzi …
Therefore, the present work aimed to compare employing histochemistry and immunohistochemistry, the number of mast cells and the content of …
Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma.
Rose JS, Serna DS, Martin LK, Li X, Weatherby LM, Abdel-Misih S, Zhao W, Bekaii-Saab T. Rose JS, et al. Cancer. 2012 Dec 15;118(24):6243-52. doi: 10.1002/cncr.27666. Epub 2012 Jun 6. Cancer. 2012. PMID: 22674181 Free PMC article.
The prognostic value of KRAS in metastatic disease, specifically according to whether patients have synchronous or metachronous disease at presentation, is less understood. METHODS: One-hundred ten consecutive patients with metastatic colorectal adenocarcinoma …
The prognostic value of KRAS in metastatic disease, specifically according to whether patients have synchronous or metachronous disease at p …
Tumor Deposits and Perineural Invasion had Comparable Impacts on the Survival of Patients With Non-metastatic Colorectal Adenocarcinoma: A Population-Based Propensity Score Matching and Competing Risk Analysis.
Luo B, Chen X, Cai G, Hu W, Li Y, Wang J. Luo B, et al. Cancer Control. 2022 Jan-Dec;29:10732748211051533. doi: 10.1177/10732748211051533. Cancer Control. 2022. PMID: 35157532 Free PMC article.
BACKGROUND: Both tumor deposits (TD) and perineural invasion (PNI) have been identified as risk factors for poor survival in patients with non-metastatic colorectal adenocarcinoma (CRC). However, the adverse impacts of TD and PNI on the survival of patients w …
BACKGROUND: Both tumor deposits (TD) and perineural invasion (PNI) have been identified as risk factors for poor survival in patients with n …
Prognostic value of metastatic pattern in colorectal cancer: a multicenter retrospective analysis in a real-life cohort.
Rumpold H, Kirchweger P, Niedersüß-Beke D, Falch D, Wundsam H, Metz-Gercek S, Piringer G, Thaler J. Rumpold H, et al. Acta Oncol. 2021 Feb;60(2):180-186. doi: 10.1080/0284186X.2020.1837945. Epub 2020 Oct 23. Acta Oncol. 2021. PMID: 33095652
We aim to determine the distribution of metastases, their dynamics during disease and their prognostic impact for specific clinical treatment scenarios (resection of metastasis and/or systemic treatment, best supportive care). MATERIAL AND METHODS: 978 patients diagnosed with …
We aim to determine the distribution of metastases, their dynamics during disease and their prognostic impact for specific clinical treatmen …
A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
Baretti M, Karunasena E, Zahurak M, Walker R, Zhao Y, Pisanic TR 2nd, Wang TH, Greten TF, Duffy AG, Gootjes E, Meijer G, Verheul HMW, Ahuja N, Herman JG, Azad NS. Baretti M, et al. Clin Transl Sci. 2021 May;14(3):954-963. doi: 10.1111/cts.12960. Epub 2021 Apr 3. Clin Transl Sci. 2021. PMID: 33811727 Free PMC article. Clinical Trial.
We previously reported CHFR methylation in a subset of colorectal cancer (CRC; 30%) with high concordance with microsatellite instability (MSI). We also showed that CHFR methylation predicted for sensitivity to docetaxel, whereas the MSI-high phenotypes were sensitive to g …
We previously reported CHFR methylation in a subset of colorectal cancer (CRC; 30%) with high concordance with microsatellite instability (M …
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system.
Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, Geller DA, Gayowski TJ, Fung JJ, Starzl TE. Iwatsuki S, et al. J Am Coll Surg. 1999 Sep;189(3):291-9. doi: 10.1016/s1072-7515(99)00089-7. J Am Coll Surg. 1999. PMID: 10472930 Free PMC article.
Although various prognostic risk factors have been identified, there has been no dependable staging or prognostic scoring system for metastatic hepatic tumors. STUDY DESIGN: Various clinical and pathologic risk factors were examined in 305 consecutive patients who u …
Although various prognostic risk factors have been identified, there has been no dependable staging or prognostic scoring system …
Expression of SATB2 in Neuroendocrine Carcinomas of the Lung: Frequent Immunopositivity of Large Cell Neuroendocrine Carcinoma with a Diagnostic Pitfall.
Inoue H, Matsushima J, Kobayashi S, Sairenchi T, Hirata H, Chida M, Ota S, Ban S, Matsumura Y. Inoue H, et al. Int J Surg Pathol. 2022 Apr;30(2):151-159. doi: 10.1177/10668969211065757. Epub 2021 Dec 16. Int J Surg Pathol. 2022. PMID: 34913369
Furthermore, two LCNEC cases were positive for CDX2 while no positive findings were observed for any SCLC cases, the difference of which, however, was not statistically significant (P = 0.053). ...These results require our attention when we use SATB2 and CDX2 as colorectal …
Furthermore, two LCNEC cases were positive for CDX2 while no positive findings were observed for any SCLC cases, the difference of wh …
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD.
Aparicio T, Darut-Jouve A, Khemissa Akouz F, Montérymard C, Artru P, Cany L, Romano O, Valenza B, Le Foll C, Delbaldo C, Falandry C, Norguet Monnereau E, Ben Abdelghani M, Smith D, Rinaldi Y, Père Verge D, Baize N, Maillard E, Dohan A, Des Guetz G, Pamoukdjian F, Lepage C. Aparicio T, et al. J Geriatr Oncol. 2020 Nov;11(8):1255-1262. doi: 10.1016/j.jgo.2020.04.001. Epub 2020 Apr 22. J Geriatr Oncol. 2020. PMID: 32334940 Free article. Clinical Trial.
The median time to autonomy degradation and quality of life degradation was 3.1 and 3.2 months, respectively. A grade 3-4 treatment-related adverse events was observed in 35/42 patients, notably: fatigue (45.2%), hand-foot skin reaction (19.0%), hypertension (21.4%), and d …
The median time to autonomy degradation and quality of life degradation was 3.1 and 3.2 months, respectively. A grade 3-4 treatment-related …
41 results